Subscribe To
LTRN / 3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True
LTRN News
By InvestorPlace
August 28, 2023
3 AI Stocks That Still Trade Under $10 Per Share
The artificial intelligence ( AI ) boom is far from over. For example let's look at Nvidia (NASDAQ: NVDA ), where CEO Jensen Huang still believes his more_horizontal
By Seeking Alpha
August 9, 2023
Lantern Pharma Inc. (LTRN) Q2 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Leber – Investor Relations more_horizontal
By InvestorPlace
August 9, 2023
3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True
As we forge ahead into the AI era, the top AI penny stocks have become increasingly relevant, emerging as a buzzword among savvy investors. Projected more_horizontal
By InvestorPlace
August 1, 2023
3 AI Stocks to Buy Under $10 in August 2023
The bull market in artificial intelligence is just getting started. In fact, with the boom only set to accelerate, we may be looking at a $1.81 trilli more_horizontal
By Seeking Alpha
May 13, 2023
Lantern Pharma Inc. (LTRN) Q1 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Asso more_horizontal
By Seeking Alpha
March 20, 2023
Lantern Pharma Inc. (LTRN) Q4 2022 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2022 Results Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Rel more_horizontal
By Pulse2
March 20, 2023
LTRN Stock: 7.74% Increase After Hours Explanation
The stock price of Lantern Pharma Inc (NASDAQ: LTRN) increased by 7.74% after hours in the most recent trading session. This is why. more_horizontal
By Business Wire
March 15, 2023
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artific more_horizontal